• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.780 +0.040 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 Next >
News headline image
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
October 07, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 06, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
June 25, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
May 07, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
April 23, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
March 27, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
March 03, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
February 25, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Provides 2025 Corporate and Financial Update
January 13, 2025
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
December 03, 2024
From Whitefort Capital Management, LP
Via Business Wire
News headline image
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
November 26, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
November 15, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
November 15, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Arbutus to Present at Jefferies London Healthcare Conference
November 14, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 06, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
October 23, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
October 15, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 01, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Participate in Two Upcoming Investor Conferences
September 03, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
July 18, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
June 06, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
June 05, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Participate in Jefferies Global Healthcare Conference
May 29, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present Imdusiran Data at EASL Congress 2024
May 22, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
May 17, 2024
From Whitefort Capital Management, LP
Via Business Wire
News headline image
Arbutus to Participate in Two Upcoming Investor Conferences
May 07, 2024
From Arbutus Biopharma Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap